title: Clinical experience with an ethinyl estradiol-desogestrel oral contraceptive.
abstract: Desogestrel (150 micrograms), a potent progestogen virtually devoid of androgenic activity, was used in combination with 30 micrograms ethinyl estradiol as an oral contraceptive preparation (Marvelon). 219 women completed a total of 4074 cycles, and the use-effectiveness was 0.58 Pearl Units. Serious side effects were not observed. The drug-related discontinuation index was 12.8% in six months.
authors.affiliation: Department of Obstetrics, University Hospital, Gent, Belgium.
authors.forename: Y
authors.initials: Y
authors.lastname: Van Trappen
authors.forename: P
authors.initials: P
authors.lastname: Duvivier
authors.forename: M
authors.initials: M
authors.lastname: Thiery
authors.forename: H
authors.initials: H
authors.lastname: Van Kets
authors.forename: P
authors.initials: P
authors.lastname: Defoort
authors.forename: W
authors.initials: W
authors.lastname: Parewijck
authors.forename: R
authors.initials: R
authors.lastname: Derom
authors.forename: G
authors.initials: G
authors.lastname: Kermans
authors.forename: P
authors.initials: P
authors.lastname: Schoofs
mesh_terms: D000328:Adult; D000367:Age Factors; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects; D017135:Desogestrel; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D009652:Norpregnenes / Q000009:adverse effects; D011247:Pregnancy; D045167:Progesterone Congeners / Q000009:adverse effects; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
chemical_list: D003280:Contraceptives, Oral, Synthetic; D009652:Norpregnenes; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol; D017135:Desogestrel